The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

The global checkpoint inhibitor refractory cancer market is experiencing significant growth, with an expected valuation of USD 38.69 billion in 2023. This expansion is fueled by the rising health ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Luca Mining Corp. ("Luca" or the "Company") is pleased to announce that Luca investors, including certain insiders, have exercised an aggregate of 38.8 million share purchase warrants worth USD$14.0 ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...